65岁及以上低危ER阳性早期乳腺癌女性中,单纯超大分割全乳放疗与单纯内分泌治疗或联合治疗的性价比分析
该成本-效用分析用马尔可夫微观模拟模型,比较65岁及以上pT1-2N0 ER阳性浸润性导管癌保乳术后负切缘患者的三种策略:5次三维适形超大分割全乳放疗不加boost(单纯放疗)、阿那曲唑5年(单纯AI)、两者联合。单纯放疗费用最低(14775美元),并优于单纯AI(ICER -5089美元);联合治疗费用最高(19802美元),较单纯放疗的ICER为113468美元,超过10万美元/QALY的性价比阈值。
要点
- 单纯超大分割全乳放疗费用最低(14775美元),单纯AI为14998美元,联合治疗最高(19802美元)。
- 单纯放疗优于单纯AI(ICER -5089美元);联合治疗较单纯放疗的ICER为113468美元,超过10万美元/QALY阈值。
- 联合治疗较单纯AI的ICER为54451美元;概率敏感性分析中单纯放疗在50%的模拟中具有性价比。
核心结论
- 对于这些低危患者,单纯超大分割全乳放疗似乎是比单纯AI更具性价比的降阶治疗策略。
- 联合超大分割全乳放疗与AI费用更高,但部分患者可能更倾向于选择联合治疗。
研究设计与样本
- 采用马尔可夫微观模拟模型,模拟65岁及以上pT1-2N0 ER阳性浸润性导管癌保乳术后负切缘女性的三种治疗策略。
- 三种策略为:5次三维适形超大分割全乳放疗不加boost(单纯放疗)、阿那曲唑5年不加放疗(单纯AI)、两者联合。
- 联合策略根据试验结果校准,单纯放疗与单纯AI的相对有效性从既往随机试验推断。
- 主要终点为终生时间范围内三种策略的增量成本-效用比(ICER),以10万美元/质量调整生命年视为具有性价比。
主要发现
- 平均而言,单纯放疗费用最低(14775美元),单纯AI略高(14998美元),联合治疗费用最高(19802美元)。
- 单纯放疗优于单纯AI(ICER -5089美元)。
- 联合治疗较单纯放疗的ICER为113468美元,略高于预设的性价比定义。
- 联合治疗较单纯AI的ICER为54451美元,具有性价比。
- 概率敏感性分析显示,单纯放疗在50%的模拟中具有性价比,联合治疗为36%,单纯AI为14%。
关键数值与推荐
- 以10万美元/质量调整生命年作为具有性价比的阈值。
- 单纯放疗优于单纯AI的ICER为-5089美元。
- 联合治疗较单纯放疗的ICER为113468美元。
- 联合治疗较单纯AI的ICER为54451美元。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The optimal management of early-stage, low-risk, hormone-positive breast cancer in older women remains controversial. Recent trials have shown that 5-fraction ultrahypofractionated whole-breast irradiation (U-WBI) has similar outcomes to longer courses, reducing the cost and inconvenience of treatment. We performed a cost-utility analysis to compare U-WBI to hormone therapy alone or their combination. METHODS AND MATERIALS: We simulated 3 different treatment approaches for women age 65 years or older with pT1-2N0 ER-positive invasive ductal carcinoma treated with lumpectomy with negative margins using a Markov microsimulation model. The strategies were U-WBI performed with a 3-dimensional conformal technique over 5 fractions without a boost ("radiation therapy [RT] alone"), adjuvant hormone therapy (anastrozole for 5 years) without RT ("aromatase-inhibitor [AI] alone"), or the combination of the 2. The combination strategy was calibrated to match trial results, and the relative effectiveness of the RT alone and AI alone strategies were inferred from previous randomized trials. The primary endpoint was the cost-effectiveness of the 3 strategies over a lifetime horizon as measured by the incremental cost-effectiveness ratio (ICER), with a value of $100,000/quality-adjusted life-year deemed "cost-effective." RESULTS: The model results compared with the prespecified target outcomes. On average, RT alone was the least expensive strategy ($14,775), with AI alone slightly more ($14,998), and combination therapy the costliest ($19,802). RT alone dominated AI alone (the incremental cost-effectiveness ratio [ICER] -$5089). Combination therapy, compared with RT alone, was slightly more expensive than our definition of cost-effective (ICER $113,468) but was cost-effective compared with AI alone (ICER $54,451). Probabilistic sensitivity analysis demonstrated RT alone to be cost-effective in 50% of trials, with combination therapy in 36% and AI alone in 14%. CONCLUSIONS: U-WBI alone appears the more cost-effective de-escalation strategy for these low-risk patients, compared with AI alone. Combining U-WBI and AI appears more costly but may be preferred by some patients.
引用
- Ward MC, Recht A, Vicini F, et al. Cost-Effectiveness Analysis of Ultra-Hypofractionated Whole Breast Radiation Therapy Alone Versus Hormone Therapy Alone or Combined Treatment for Low-Risk ER-Positive Early Stage Breast Cancer in Women Aged 65 Years and Older. Int J Radiat Oncol Biol Phys. 2022. PMID: 36586492. doi:10.1016/j.ijrobp.2022.12.028
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。